The multi-disciplinary Cardiac Amyloidosis Clinical Center offers state-of-the-art diagnosis and management of patients with cardiac amyloidosis. The Center serves a growing need for clinical care and research driven by the recent recognition of a high prevalence of cardiac amyloidosis, made possible by developments in noninvasive cardiac imaging.
The clinic provides consultative services to:
- Facilitate the diagnosis, typing (differentiation of ATTR from AL) and characterization of suspected or known cardiac amyloidosis
- Evaluate patients for multisystem involvement
- Identify patients suitable for currently available off-label therapies for cardiac ATTR amyloidosis, and for clinical trials. There are several specific therapies for amyloid cardiomyopathy and neuropathy that are close to clinical translation.
- Facilitate participation in the cardiac amyloidosis registry and biobank
Heart and Vascular Insitute
Clinical consultative services in the Cardiac Amyloidosis Clinical Center are provided by:
Prem Soman, MD, PhD, and William Follansbee, MD (Cardiology)
Sasa Zivkovic, MD (Neurology)
Alison Sehgal, MD (Hematology)
Roderick Tan, MD (Nephrology)
Kapil Chopra, MD (Hepatology)
Consultative services are supported by advanced nuclear cardiology, cardiac magnetic resonance, and echocardiography imaging services.